INTRODUCTION

Genome-wide association studies (GWAS) in European and
5048-5055 doi:10.1093/hmg/ddt337 Advance Access published on July 12, 2013 no known biological function and they together only account for a small proportion of CRC heritability (9, 13) . Findings from the first wave of GWAS are expected to open up new windows into disease biology; however, at present, the identities of the causal variants remain undetermined for most risk loci. Studies in populations of African ancestry are likely to provide additional insights in that: (i) it is possible to narrow the large chromosomal regions of association and pinpoint the best risk-defining variants, a benefit of the shorter average linkage disequilibrium (LD) blocks in this population (14) ; and (ii) the greater genetic diversity in African-descent populations may help to identify additional susceptibility variants.
In this study, we tested the 29 GWAS-identified CRC risk SNPs (21 regions) in a large sample set of African Americans (1894 cases and 4703 controls) and searched for additional or more predictive risk variants in the surrounding regions (+250 kb) using genotyped and imputed markers at the density of the 1000 Genomes Project (1KGP).
RESULTS
The African American CRC cases and controls in this analysis are from seven studies/centers in the USA (Supplementary Material, Methods and Table S1 ). Samples were genotyped using the Illumina 1M-Duo bead array (except 170 subjects on Omni 2.5 M). After quality control (QC) exclusions (see Methods), the analysis was performed on 1894 cases and 4703 controls; the number of right colon, left colon and rectal cases (mutually exclusive) was 778, 500 and 399, respectively. On average, cases were older than controls (mean 68 and 62 years, respectively) and the proportion of females was higher in cases (49.6%, compared to 35.2% in controls). Cases and controls were similar in global ancestry distribution based on principal components (PCs) (Methods, Supplementary Material, Fig. S1 ). We adjusted for age, sex and the first four most important PCs in logistic regression and little inflation of test statistics due to population stratification was observed (genomic control l ¼ 1.04).
Among the 29 CRC risk variants ( Given the strong prior evidence for the directions of these genetic effects, we considered as statistically significant replication if the odds ratio (OR) estimates in African Americans were of the same direction as reported in the original GWAS with a one-sided P-value , 0.05 (or equivalently with a two-sided P-value , 0.10). Nine variants were replicated at this level. These included rs7758229 on 6q26-27 that was previously reported to be associated only with distal (left) colon cancer in East Asians [C/A, OR ¼ 1.28 in (2)]-in our data, the OR of the risk allele C was 1.23 (95% CI: 1.00-1.51, two-sided P ¼ 0.056 with 500 left colon cases and all controls). These 9 and additional 15 variants showed the same direction of allelic risk as reported before (24 of 29, 83%; Table 1 ). Estimated locusspecific ancestry (see Methods) (including 250 kb on both sides of the index variants) was not associated with CRC after adjustment for age, gender and the first four PCs-only two strong associations were observed for 19q13.1 (P ¼ 0.003) and Xp22.2 (P ¼ 0.04). Results for the index SNPs were similar with or without adjustment for local ancestry (Table 1 ).
Significant heterogeneity of effects across anatomic subsites (left colon, right colon and rectal cancer) was detected for rs10411210 at 19q13 and rs1321311 at 6p21 (P heterogeneity ¼ 0.03 and 0.04, respectively). Stratified analyses by site showed that the rs10411210T allele was only associated with left colon cancer (OR ¼ 0.83, 95% CI ¼ 0.72 -0.95, P ¼ 0.007) and the rs1321311 A allele was only associated with rectal cancer (OR ¼ 0.85, 95% CI ¼ 0.73 -0.99, P ¼ 0.03). These sitespecific effects were of the same direction as reported in the initial GWAS.
Even with the large sample size, our power to detect the previously reported effect sizes was .80% for only 15 of the 29 index variants at a one-sided a level 0.05 (Supplementary Material, Table S2 ); among these, 7 were successfully replicated. One possible reason of non-replication could be that the biologically relevant variants are in LD (correlated) with the index variants in the original GWAS population, yet not so in African Americans. Therefore, a complete search among the correlated variants for stronger associations with CRC is necessary. We performed finemapping in the 21 risk regions/loci (+250 kb of index variants) using genotyped and imputed data (see Methods). We catalogued SNPs that were correlated (r 2 . 0.2) with the index signals from 1KGP [Europeans (EUR) or Asians (ASN) depending upon the initial GWAS population] and tested their associations with CRC using locus-specific a levels, calculated as 0.05 divided by the 'effective' number of independent markers in the 1KGP Africans (AFR) population among the correlated markers in each region (see Methods and Table S3 for locus-specific a levels). This strategy was to balance between the need to correct for multiple comparisons and the prior knowledge that these regions are known to be important for CRC risk.
Among the correlated SNPs, two variants in the 1q41 and 19q13.1 loci passed the significance threshold (Table 2) . Specifically, at 1q41, the original risk variants rs6691170 and rs6687758 were not replicated in African Americans (OR ¼ 1.02 and 0.99, P . 0.7, power ≤ 56%); rs12759486 (T/C) located between the two was much more strongly associated with CRC (OR ¼ 0.86, 95% CI ¼ 0.79 -0.93, P ¼ 1.5 × 10 24 ) in our study (Fig. 2 ). Rs6691170 and rs6687758 were in low LD with each other (r 2 ¼ 0.13, D ′ ¼ 0.59) in EUR and the original GWAS in Europeans (4) suggested that they may represent independent signals of association. From LD structure based on 1KGP data, rs6691170 and rs6687758 are in separate (but not completely distinct) LD blocks in both EUR and AFR (Supplementary Material, Fig. S2 ). Rs12759486 is located between the two and is in moderate LD with both of them in EUR (r 2 ¼ 0.37 and 0.22, respectively) but not so in AFR , OR ¼ 0.85 for major allele C). Rs7547751 maps to H3K4me1 and H3K27Ac enhancer peaks with a nearby DNAse I peak and CTCF and cohesion/ Rad21 binding sites determined by ChIP-seq (15) . Based on these data, it is possible that this enhancer may modulate lincRNA RP11-815M8.1 or a protein-coding gene in trans.
At 19q13.1 in African Americans, the published hit, rs10411210, had a P-value of 0.11 using all cases combined (OR ¼ 0.94, 95% CI ¼ 0.86-1.02, power ¼ 0.97). Rs7252505, 43 kb downstream from rs10411210, was more strongly associated with CRC (OR ¼ 0.85, 95% CI ¼ 0.78-0.93, P ¼ 1.8 × 10
24
) in African Americans (Fig. 3 ). Rs7252505 and rs10411210 were correlated in EUR (r 2 Fig. S3 for LD structure in 1KGP).
These results raise the possibility that the original GWAS signals in 1q41 and 19q13 may not have captured the best predictive risk markers. Results for the two best markers in African Americans did not change much (,3% change in ORs) after conditioning on the index variants or after adjusting for local ancestry.
We also looked for new independent associations among variants that were uncorrelated (r 2 , 0.2) with the index SNPs in the initial GWAS populations, using a significance level of 2.8 × 10
26
, which is 0.05/the total number of 'effective' markers across the 21 risk regions in the 1KGP YRI population (Methods and Table S3 ). We did not find any statistically significant associations among SNPs in this category.
To model the cumulative effects of CRC risk variants, we constructed a risk score by summing all independent risk alleles (OR .1) and estimated the average per allele risk (see Methods). We compared the results from summing all GWAS-identified risk variants (n ¼ 21 independent) and from summing the variants that were replicated (n ¼ 7) or newly discovered (n ¼ 2) in African Americans (Methods and Table 3) , excluding the one SNP on 6q26-q27 that was only associated with distal colon cancer in the original GWAS (2) . From 21 GWAS index variants, the per allele OR was 1.07 (95% CI:
); the OR for the highest versus the lowest quartile of the risk score was 1.72 (95% CI: 1.44 -2.06, P ¼ 1.9 × 10 29 ). As expected, there was a slight increase in relative risk when summing risk variants replicated or newly discovered in African Americans: the per allele OR was 1.14 (95% CI: 1.10-1.18, P ¼ 6.5 × 10
216
) and the OR for the highest versus lowest quartile of the score was 1.83 (95% CI: 1.55-2.16, P ¼ 1.1 × 10
212
). The risk score effect did not differ across left colon, right colon or rectal cancer (P heterogeneity ¼ 0.54).
The two novel variants rs12759486 and rs7252505 contributed approximately 1.5% of the heritability of CRC (see Methods), estimated in African Americans.
DISCUSSION
It is important to assess the strength and robustness of GWAS-identified association signals in diverse ethnic Analysis conditioning on the index SNPs from the initial GWAS study. Figure 2 . P-value plot for the 1q41 risk locus. The SNP with the smallest P-value in African Americans, rs12759486, is shown as a purple diamond. r 2 is in relation to this SNP in EUR from the 1000 Genomes Project. Grey circles are SNPs with no r 2 estimation due to low MAF or because the SNP is not in older versions of the 1000 Genomes data. The plot was generated using LocusZoom (16) .
populations. This study, to our knowledge, is the first to replicate and characterize risk variants identified from CRC GWAS (all in European and Asian populations) in African Americans with a relatively large sample size. Nine associations were statistically significantly replicated with the same direction of effects as previously reported (one-sided P , 0.05). We also identified variants in 1q41 (rs12759486 or rs7547751, two SNPs in perfect LD) and 19q13.1 (rs7252505) that were more strongly related to CRC in African Americans than the index variants (three orders of magnitude change in P-value). These two new risk variants explained roughly 1.5% of overall CRC heritability in African Americans and improved on cumulative risk modeling. Failure to replicate other previous associations may be due to low study power (,80% for half of the variants) or to differences in LD patterns between the causal variant and the identified marker between populations-the latter is a known cause for directionally inconsistent associations across studies (a.k.a. the flip-flop phenomenon) (17) . No statistically significant reverse association was noted, however.
We detected significant heterogeneity of effects across left colon, right colon and rectal cancer for rs10411210 in RHPN2 at 19q13 and rs1321311 near CDKN1A at 6p21 (P heterogeneity , 0.05). Although they were not statistically significantly replicated when all cases were pooled, rs10411210 was associated with left colon cancer and rs1321311 with rectal cancer (P's , 0.05) in African Americans. In the GWAS where rs10411210 was first reported for CRC association, there was no mention of effect heterogeneity across subsites (although the betweenstudy heterogeneity seemed high) (5) . Several replication studies conducted in Northern Chinese (18) , Southern Chinese (19), Hong Kong subjects (20) and in a Swedish-based cohort (21) have been published for rs10411210; however, none of these replicated the association or reported on differences in effect across subsites. A reason for failure to replicate may be due to effect heterogeneity. In a study ( 1000 cases) on clinical and morphological characters of CRC tumors and genetic variation, the TT genotype of rs10411210 was associated with desmoplastic reaction, which is generally considered favorable for survival (22) . For rs1321311, we did not find studies including specific results other than the original GWAS, which only reported that this SNP was not associated with tumor location (colon and rectum). Risk heterogeneity by CRC subsites has been previously reported for GWAS index variants. For example, the risk for rs4939827 was greater for rectal cancer than for colon cancer in a GWAS (statistically non-significant heterogeneity) (7); yet, in a replication study in Europeans, this SNP was associated with distal colon cancer but not proximal or rectal cancer (P heterogeneity ¼ 0.03) (23) . In our data, there did not seem to be effect heterogeneity for rs4939827 by subsites (P ¼ 0.23). However, for the SNP rs7758229 at 6q26 that was reported to be only related to left colon cancer in a GWAS in East Asians (2), no heterogeneity across sites was found in our data (P heterogeneity ¼ 0.35), even though we replicated its association with left colon cancer (one-sided P , 0.05) and not with right-sided colon or rectal cancers (P's . 0.41). Sample size could be a reason for these inconsistencies and additional large replication studies are needed.
At 19q13 (index SNP rs10411210), rs7252505 was more strongly associated with CRC in African Americans, with no evidence of heterogeneity across anatomical subsites (P heterogeneity ¼ 0.78). While rs10411210 is located in RHPN2, rs7252505 is in an intron of the neighboring gene GPATCH1. Although GPATCH1 is expressed in the colon, little is known about its function other than the fact that it contains a G-patch domain, a domain typically associated with RNA processing. Rs7252505 or SNPs in high LD (r 2 . 0.8) with it in 1KGP AFR do not map to any ChIP-seq peaks marking Figure 3 . P-value plot for the 19q13 risk locus. The SNP with the smallest P-value in African Americans, rs7252505, is shown as a purple diamond. r 2 is in relation to this SNP in EUR from the 1000 Genomes Project. Grey circles are SNPs with no r 2 estimation due to low MAF or because the SNP is not in older versions of the 1000 Genomes data. The plot was generated using LocusZoom. (24) . Our approach of separating SNPs that are in LD from those not in LD with the index SNPs and testing the two groups with different significance thresholds was a reasonable balance between prior knowledge and the need for multiple comparison adjustment. However, the two groups may not have been correctly defined even with the detailed coverage featured by currently available public data. For example, we replicated the index SNP rs16892766 at 8q23 with a P-value 0.006 (minor/ major ¼ C/A, MAF ¼ 0. After conditioning on each other, the P-values became even smaller (10 26 for rs16892769 and 0.0004 for rs16892766) and did not change much with additional adjustment for local ancestry. Generally, SNPs within such short distance are likely inherited together because physical chromosomal structure typically prevents recombination events. In 1KGP AFR, the two SNPs are indeed in high LD (D ′ ¼ 1, r 2 ¼ 0.05, P , 0.0001 from Pearson's correlation test). However, because rs16892769 was monomorphic in Europeans in both HapMap and 1KGP, no LD estimation was available; hence, rs16892769 was defined as 'uncorrelated' with the index variant and did not pass the corresponding more stringent significance threshold. Given its rarity or non-existence in Europeans, rs16892769 is unlikely a causal variant in this population. In African Americans, haplotype analysis revealed three common haplotypes AT, AG and CT, with frequency 0.75, 0.12 and 0.13, respectively; compared to AT, the haplotype AG had an OR of 1.30 (P ¼ 3.2 × 10 25 ), suggesting some independent effect for the G allele of rs16892769. There has been no report on the association between rs16892769 and CRC. However, this SNP may be worth investigating in future studies in light of our results. On the other hand, the threshold (r 2 . 0.2) for defining markers correlated with the index variants may be too low. If a higher threshold is used (such as r 2 . 0.4), our best marker at 1q41, rs12759486, would be classified as 'non-correlated' and would not pass the more stringent significance level for this category. Hence, some caution should be exercised in interpreting our results. On a related note, the effect sizes of our two best SNPs (rs12759486 and rs7252505) may be over-estimated due to the 'winner's curse' (25 -27) .
In summary, we confirmed in African Americans the risk directions for 83% of the 29 CRC variants identified in previous GWAS and successfully replicated an association for nine of them. No population-specific (except for the possibility of an association with rs16892769) or novel risk loci were discovered. However, at two known loci, we identified two markers that may better define CRC risk than the previous index SNPs. Replication in additional studies is required to confirm these effects.
MATERIALS AND METHODS
Subjects and genotyping and QC
DNA samples were available for 7339 African Americans (2066 CRC cases, 5273 CRC-free controls) from the following studies/ centers: the Multiethnic Cohort study (MEC, 442 cases and 4620 controls), Colorectal Cancer Family Registry (CCFR, 999 cases and 290 controls), the Southern Community Cohort Study (SCCS, 164 and 160 controls), MD Anderson Cancer Center (189 cases), the University of North Carolina CanCORS study (UNC-CanCORS, 84 African American cases), the North Carolina Rectal Cancer Study (UNC-Rectal, 112 cases and 108 controls), the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO, 76 cases and 95 controls). See Supplementary Material for details on sample recruitment and data collection.
Except for the PLCO subjects (see below), 7168 samples were genotyped using the Illumina 1M-duo bead array at the USC Epigenome Center. Samples were excluded in the following situations: (i) call rates , 95% (n ¼ 167), (ii) no age information (n ¼ 2), (iii) gender mismatch (n ¼ 39), i.e. when the reported gender is different from that estimated based on X chromosome inbreeding coefficient F (calculated by PLINK), (iv) ancestry outliers (n ¼ 98) based on PCs (discussed below), and (v) closer than second-degree relatives (n ¼ 435), where relationships were derived from estimated probabilities of sharing 0, 1 or 2 allele based on genomic data (calculated by PLINK). Relatives were removed in the following order or priority: (i) subjects with many relatives, (ii) controls, (iii) samples with lower call rates. Sample replicates (2%) were included and the average concordance rates were .99.9%. Starting from 1 192 666 markers, we excluded markers of poor clustering property or with call rates ,95%, MAFs ,0.005, more than one discordant pair among sample replicates, and P-values , 10
210 from the Hardy-Weinberg equilibrium test in MEC controls and of poor clustering quality. These resulted in 6427 subjects (4609 controls and1818 cases) on 1 049 327 markers.
PLCO subjects (n ¼ 171) were genotyped by the NCI genotyping center on the Illumina Omni 2.5 M array and were pre-filtered by the PLCO data coordinating center using similar criteria as described above. We removed one subject to get rid of closer than second-degree relatives. For this analysis, 76 cases and 94 controls on 527 383 markers that overlapped with other studies were retained. Allele frequencies matched well between PLCO and MEC controls (only 77 differences were .0.1 and all were ≤0.13).
Statistical analysis
Association testing Logistic regression of allelic dosage with adjustment for age at blood draw, sex and the first four PCs was performed to estimate the OR and 95% CI of per increase in allele count, where age was grouped as ,55 years, 5-year intervals from 55 to 80, and ≥80 years. Heterogeneity of genetic effects across left colon, right colon and rectal cancer (mutually exclusive) was assessed with multinomial logistic regression with SAS 9.2. PCs were calculated using similar methods as in (28) Fig. S1 ). The first six PCs sequentially accounted for 2.35, 0.52, 0.10, 0.10, 0.09 and 0.09% of the total variation, which, together with pair-wise PC plots, suggested that the first four PCs were most informative for global ancestry. All P-values presented are two-sided, unless otherwise noted.
Local ancestry estimation
The percentage of African ancestry (0, 50 or 100%, i.e. half of the estimated number of African chromosomes) was inferred for each participant at each marker location with the LAMP program v2.4 (29) . For the one region on Chromosome X, local ancestry was separately estimated for males and females. To summarize local ancestry at a CRC risk region, for each individual we averaged across all local ancestry estimates that are within the start and end points of the region (Supplementary Material, Table S3 ). We evaluated whether ORs changed with and without adjustment for local ancestry in logistic regression. Since they did not change materially, we presented results without adjustment for local ancestries, unless otherwise noted.
Imputation
Prediction of un-genotyped SNPs was performed with BEAGLE 3.3 (30) based on the 1000 Genomes EUR and AFR reference panels (phase 1, release 3). Markers with MAFs ,0.005 in both EUR and AFR reference panels were excluded from imputation. 10 050 748 markers with imputation accuracy R 2 . 0.8 were kept for association analysis.
Fine mapping
We conducted fine mapping in regions within 250 kb of previously identified risk variants. If the regions overlapped for multiple risk variants (i.e. when they are ,500 kb apart), one larger region was formed from 250 kb upstream of the first to 250 kb downstream of the last variant (see Supplementary Material, Table S3 for risk regions). For each region, we catalogued SNPs that were correlated (r 2 . 0.2) with the index signal in the initial GWAS population (EUR or ASN) in 1KGP (phase 1, release 3). Locus-specific significance levels, 0.05/the 'effective' number of independent markers in the 1KGP AFR population among the correlated markers in each region, were used to declare a better marker than the index SNPs in a region. For variants that were uncorrelated with the index signal in the initial GWAS populations (r 2 , 0.2), we estimated the total number of effective markers across all risk regions in 1KGP YRI and used a significance level of 2.8 × 10 26 (0.05/the total number of independent SNPs) in claiming novel association signals. The number of markers correlated and uncorrelated with previous hits and the 'effective' number of SNPs in each region are shown in Supplementary Material, Table S3 . The number of independent SNPs was estimated with Keffective (31) .
We performed stepwise logistic regression to select among SNPs (dosages) in each region separately for correlated and uncorrelated SNPs, using the significance levels described above. To preserve sample size, sporadic missing values for genotyped markers were replaced with mean allele dosages in their corresponding sex group. One SNP from locus 6q26-27 was previously reported to be associated only with distal (left) colon cancer in East Asians (2) so only association with distal colon cancer was assessed for this variant, unless otherwise noted.
Risk modeling
A risk score was calculated summing the risk (OR . 1) alleles from independent markers. The OR of per one allele increase in the risk score was estimated as an average cumulative risk of all contributing markers. Here, we excluded the one SNP on 6q26-q27 associated with only distal colon cancer in the original GWAS. This sum was calculated first based on previous GWAS hits (n ¼ 21). There are six regions containing multiple risk SNPs; these SNPs are in LD (r 2 . 0.2) in the initial GWAS population except the two in 20p12.3 (defined in Table 1 ). Both SNPs in 20p12.3 were included; for the remaining five regions, the SNP with the smallest P-value was included since likelihood ratio tests showed that the contribution of other variants in the same region was not important (x 2 's , 0.69, P's . 0.41). Independence of SNPs on the same chromosome was confirmed by comparing regression coefficients from single variant analysis and from the model including all markers on the same chromosome. A sum was similarly calculated with the variants replicated (n ¼ 7 independent) and newly identified (n ¼ 2) in African Americans. Missing values for ungenotyped markers were replaced with mean allele dosages in their corresponding sex group.
Heritability explained by the newly discovered variants in African Americans
The sibling relative risk attributable to a given SNP was calculated using the formula as in (9, 32) , l * ¼ ( p( pr 2 + qr 1 ) 2 + q( pr 1 + q)
2 )/( p 2 r 2 + 2pqr 1 + q 2 ) 2 ,where p is the population frequency of the risk allele (OR . 1), q ¼ 1 2 p, and r 1 and r 2 are the relative risks (estimated as OR) for heterozygous and homozygous genotypes containing the risk allele. For imputed markers, we used the probabilities of heterozygotes and homozygotes in regression models to obtain r 1 and r 2 . Assuming a multiplicative effect, the proportion of the familial risk attributable to a SNP was calculated as log(l * )/log(l 0 ), where l 0 is the overall familial relative risk estimated from epidemiological studies of CRC, assumed to be 2.2 (32, 33) .
